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Available online 15 January 2016Background: To further understandmanagement of pediatric patientswithmultiple sclerosis (MS), we examined
disease features, clinical practice patterns, and response to treatment in the United States (US) and seven other
countries (‘rest of World’; ROW).
Methods: Anonymized data, recorded as part of routine clinical practice, were obtained from medical records
(1997–2009) of study participants (who received subcutaneous interferon β-1a before age 18 years) from the
US and ROW. Samples were stratiﬁed by age (preadolescents [b12 years] and adolescents [12–17 years]).
Results:US adolescents had a highermean bodymass index versus ROWadolescents (BMI; 27.2 versus 22.5 kg/m2),
started disease-modifying therapy (DMT) earlier after the ﬁrst relapse, weremore likely to have received a DMT
before initiating subcutaneous interferon β-1a, had a higher relapse rate, and were more likely to switch from
subcutaneous interferon β-1a to another DMT before the end of the observation period.
Conclusions: This retrospective analysis of a multinational sample of pediatric MS patients who received subcu-
taneous interferon β-1a found that those from the US had higher BMI, relapsedmore frequently, and were man-
aged differently, compared with ROW patients. Future prospective studies are needed to conﬁrm these
observations and ascertain their clinical signiﬁcance.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Subcutaneous interferon β-1a1. Introduction
There is international consensus on the importance of initiating
disease-modifying therapy (DMT) in children and adolescents with
multiple sclerosis (MS), and on the need for collaborative prospective
research [1]. Children and adolescents with MS represent an
understudied subgroup, largely due to the low frequency of MS in this
age group. The incidence of MS in children and adolescents is estimateddy mass index; DMD, disease-
interferon; ME,medical events;
rd deviation; US, United States.
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. This is an open access article undeto be 0.18 to 0.51 per 100,000 [2], compared with 3.6 and 2.0 per
100,000 in women andmen, respectively, as reported in one systematic
review [3]. In recent years, the recognition of pediatric MS has grown
and data have been gathered on the demographic and clinical features
of this population from different regions of the world.
Still, it remains unclear how pediatric patients with MS respond to
DMTs and whether regional differences impact the management of
MS with DMTs. Small studies (most involving 50 or fewer participants)
have demonstrated that baseline relapse rates decrease after treatment
with DMTs [4–12]. Recently, our group, the REPLAY study investigators,
completed the largest reported retrospective analysis of treatment ex-
perience with subcutaneous (sc) interferon (IFN) β-1a in pediatric pa-
tients with MS. Based on the review of medical records from 307
pediatric patients (298 of whom had a ﬁnal diagnosis of MS) enrolled
from eight countries, we found that adult doses of sc IFN β-1a (44 and
22 μg three times weekly [tiw]) were well tolerated and associatedr the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[12]. Here we report data from post hoc analyses comparing REPLAY
participants enrolled from the United States (US) with those enrolled
from Italy, Russia, Argentina, France, Canada, Tunisia, and Venezuela,
analyzed together as the ‘rest of the world’ (ROW) group. These analy-
ses examined selected baseline clinical features, treatment practices,
and outcomes between the US and ROW, where healthcare environ-
ments vary, to determinewhether regional differences impact theman-
agement of MS with DMTs.
2. Methods
2.1. Study design
International Review Board or Independent Ethics Committee ap-
proval of the protocol was obtained from each participating site. Details
of the studymethodology have been described (NCT01207648) [12]. All
patients who had received ≥1 injection of sc IFN β-1a for demyelinating
events before the age of 18 years were eligible for inclusion, and treat-
ment with sc IFN β-1a must have been initiated before June 2009
(allowing at least 6 months of observation for each patient). The aim
was to assess all eligible patients at each center. The ﬁnal analyses
were limited to patientswho received a conﬁrmeddiagnosis ofMS only.
Data were collected from the medical records of patients evaluated
between 1997 and 2009. All analyzed information was recorded as
part of routine clinical practice. The observation period for an individual
patient began with the ﬁrst medical record available on site and ended
on 31 December 2009, or when the patient was lost to follow-up,
whichever occurred ﬁrst.
2.2. Outcomes
Baseline demographics, clinical characteristics, and treatment pat-
terns and outcomes of patients from the US and ROW were compared.
Prespeciﬁed medical events (MEs) occurring after the initiation of sc
IFN β-1a treatment (based on the known safety proﬁle of sc IFN β-1a
[13,14])were recorded. Clinical relapseswere deﬁned as the emergence
of new neurological symptoms and signs that occurred ≥30 days after
the last event and persisted for ≥24 h in the absence of intercurrent
illness.
2.3. Statistical analysis
Efﬁcacy and safety outcomes were assessed. All comparisons were
exploratory and descriptive. Interpretation of results was based on
point estimates and their corresponding 95% conﬁdence interval.
Mean and 95% CI were calculated using the Poisson model to provide
adjusted means (adjusted for baseline characteristics [region and
age]). All statistical analyses were performed using SAS version 9.1 (or
higher) software (SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Total sample of patients with pediatric MS
A total of 298 patients were conﬁrmed to have MS and were pre-
scribed sc IFN β-1a (44 or 22 μg tiw). Patients enrolled were from the
US (n= 131 [44.0%]) and ROW (n= 167 [56.0%]); the latter comprised
patients from Italy (n= 47 [15.8%]), Russia (n= 38 [12.8%]), Argentina
(n = 33 [11.1%]), France (n = 22 [7.4%]), Canada (n = 21 [7.0%]),
Tunisia (n = 3 [1.0%]), and Venezuela (n = 3 [1.0%]).
3.2. Baseline characteristics
Overall, 61.7% (184/298) of patients who had received an MS diag-
nosis were female. The mean (standard deviation) age was 12.3 (3.4)years at the ﬁrst clinical demyelinating event, 13.3 (3.1) years at MS di-
agnosis, and 14.1 (2.9) years at initiation of sc IFN β-1a treatment. A
total of 96 (37.4%) patients had a monofocal presentation, 171 (57.4%)
were hospitalized for the ﬁrst clinical demyelinating event, 177
(59.4%) received steroid treatment, and 297 (99.7%) had an initial
relapsing–remitting MS course.
3.2.1. Regional contrasts in demographic and clinical characteristics
3.2.1.1. Age. As a result of a lower proportion of children b12 years
among those enrolled from US sites compared with the ROW (15/
131 [11%] vs 35/167 [21%]), all analyses were stratiﬁed by age
group (preadolescent [b12 years] and adolescent [12–17 years]).
3.2.1.2. Demographics and clinical characteristics. Patient demographics
and clinical characteristics by region are presented in Table 1. Adoles-
cents (12–17 years) from the ROW had a disease duration prior to sc
IFN β-1a initiation that was more than twice that of adolescents from
the US (median days [range]: 164.5 [1, 3111] vs 62.0 [−116, 3638]),
and lower Expanded Disability Status Scale (EDSS) score at sc IFN β-1a
initiation (median [range]: 1.50 [0.0, 6.0] vs 2.00 [0.0, 8.0], Table 1). Pre-
adolescents (b12 years) from the ROW had fewer clinical attacks prior
to sc IFN β-1a initiation than those from the US (median [range]: 2.0
[1, 9] vs 3.0 [1, 7]). Interesting patterns emerged from analyses of
bodymass index (BMI)where these datawere available. The proportion
of missing data among adolescents was 59% and 75% from the US and
ROW, respectively (Table 1). Fortunately, there were no differences in
demographic features between participants with BMI data and those
with BMI data missing from their records. While there was little differ-
ence in BMI for the preadolescent groups, there were striking differ-
ences in the mean and median BMI among adolescents from the US
and the ROW. Adolescents from the US had mean and median values
that were at least 17% higher than those of the ROW (Table 1).
3.2.1.3. Clinical outcomes. The annualized relapse rate (ARR) prior to ini-
tiation of DMT was comparable in the US and ROW for both age groups
(mean: 1.9 and 2.1 [b12 years] and 1.7 and 1.8 [12–17 years], respec-
tively; Fig. 1). However, preadolescents from both regions had slightly
higher baseline ARR compared with adolescents.
The ARR decreased following sc IFN β-1a treatment in preadoles-
cents and adolescents from both the US and ROW (Fig. 1). However,
ARRs during sc IFN β-1a therapy were higher in the US for both age
groups, compared with in the ROW. Both age groups from the US had
a higher ARR relative to the ROW during the period between treatment
termination and the end of the observation period. The median time to
ﬁrst relapse after treatment initiation was shorter in the US
(14.2 months) than in the ROW (27.2 months).
3.2.1.4. On-study treatment patterns. Demographic and clinical features
are shown in Table 2. Adolescent patients in the US had a markedly
shorter median interval from the ﬁrst clinical demyelinating event to
initiating DMT, compared with adolescent patients in the ROW
(Table 2). Patients from the US had a greater likelihood of receiving a
different DMT preceding initiation of sc IFN β-1a. For example, 60.0%
of preadolescents and 29.3% of adolescents in the US received a prior
DMT before starting treatment with sc IFN β-1a. In contrast, only
13–14% of preadolescents and adolescents from the ROW received a
DMT prior to sc IFN β-1a treatment.
3.2.1.5. Prescribing patterns for sc IFN β-1a. A greater proportion of pa-
tients in the US received 44 μg tiw as their targeted prescribed dosage
of sc IFNβ-1a, comparedwith patients from theROW(Table 3). Patients
in the US also had a shorter time on sc IFN β-1a treatment, were less
likely to be receiving ongoing sc IFN β-1a therapy at study end, and
were more likely to have switched to another DMT during the study
period.
Table 1
Baseline characteristics and demographics among preadolescents and adolescents with multiple sclerosis, by region.
Characteristic Preadolescents (b12 years) Adolescents (12–17 years)
US (n = 15) ROW (n = 35) US (n = 116) ROW (n = 132)
Female 5 (33.3) 15 (42.9) 76 (65.5) 88 (66.7)
Age for those with BMI data, years
n (missing) 5 (10) 17 (18) 48 (68) 33 (99)
Mean (SD) 8.2 (2.8) 8.3 (3.0) 15.2 (1.5) 14.9 (1.4)
Median (range) 9.0 (4, 11) 10.0 (3, 11) 15.0 (12, 17) 15.0 (12, 17)
BMI, kg/m2
Mean (SD) 18.8 (3.8) 18.4 (2.7) 27.2 (7.5) 22.5 (3.9)
Median (range) 16.8 (15.6, 23.4) 19.2 (13.6, 22.0) 26.4 (17.3, 51.3) 22.6 (15.6, 34.2)
Monofocal 2 (15.4) 12 (34.3) 14 (17.5) 68 (52.7)
Multifocal 11 (84.6) 23 (65.7) 66 (82.5) 61 (47.3)
Disease duration pre sc IFN β-1a, days
n (missing) 15 (0) 35 (0) 116 (0) 132 (0)
Mean (SD) 176.6 (290.5) 209.5 (268.2) 196.9 (446.2) 410.0 (597.7)
Median (range) 150.0 (−395, 731) 137.0 (7, 1370) 62.0 (−116, 3638) 164.5 (1, 3111)
EDSS at sc IFN β-1a initiation
n (missing) 9 (6) 34 (1) 90 (26) 127 (5)
Mean (SD) 1.56 (1.04) 2.29 (1.23) 1.97 (1.47) 1.69 (1.07)
Median (range) 2.00 (0.0, 3.0) 2.00 (0.0, 6.0) 2.00 (0.0, 8.0) 1.50 (0.0, 6.0)
Number of clinical attacks prior to sc IFN β-1a initiation
n (missing) 15 (0) 35 (0) 116 (0) 132 (0)
Mean (SD) 3.5 (1.9) 2.7 (1.8) 2.7 (2.4) 2.7 (1.7)
Median (range) 3.0 (1, 7) 2.0 (1, 9) 2.0 (1, 22) 2.0 (1, 14)
BMI, body mass index; EDSS, Expanded Disability Status Scale; IFN β-1a, interferon β-1a; ROW, rest of the world; sc, subcutaneous; SD, standard deviation; US, United States.
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Minor differences in the overall occurrence of prespeciﬁedMEswere
observed between the US and ROW (Table 4). The most commonly re-
ported prespeciﬁed MEs in the US were injection-site reactions, follow-
ed by ‘ﬂu-like’ symptoms. In contrast, ‘ﬂu-like’ symptoms were more
common than injection-site reactions in the ROW.4. Discussion
Across the countries studied, the main conclusions from the REPLAY
study [12] are still applicable. Speciﬁcally, regardless of region, sc IFN β-
1a treatmentwaswell tolerated in preadolescents and adolescents with
MS. Treatment was also associated with a reduction in clinical relapses
compared with before treatment.Fig. 1.Medically conﬁrmed clinical relapses prior to, during, and after termination of subcutaneo
ROW, rest of the world. Values presented are mean (95% CI).Compared with the ROW, there was a lower proportion of preado-
lescent patients (aged b12 years) in the US. This could at least be partly
explained by site-speciﬁc practice patterns.
While there were limited available data, BMI was noticeably higher
among adolescents from the US, an observation that is consistent with
the current epidemic of childhood and teenage obesity in the US [15].
In 2007, 16.4% of US children were obese and 31.6% were overweight,
with substantial geographic variation [16]. Furthermore, a systematic
review showed that adolescent obesity was higher in the US than
other countries studied [17]. Childhood obesity has been associated
with an increased risk of pediatric MS [18]. In the current study, the
analyses on BMIwere limited because ofmissing data. However, clinical
and demographic features of those missing BMI data and those with
BMI data did not differ, and the extent of missing data is comparable
across regions. Future prospective international research should further
examine the association between global region, BMI, and pediatric MS.us interferonβ-1a treatment in patientswithmultiple sclerosis by country and age groups.
Table 2
Clinical management patterns for preadolescents and adolescents with multiple sclerosis at baseline, by region.
Characteristic Preadolescents (b12 years) Adolescents (12–17 years)
US (n = 15) ROW (n = 35) US (n = 116) ROW (n = 132)
Time from ﬁrst demyelinating event to ﬁrst DMT, years
Mean (SD) 1.53 (1.57) 0.65 (0.52) 0.91 (1.10) 1.75 (1.48)
Median (range) 0.77 (0.1, 4.9) 0.67 (−0.1, 1.4) 0.64 (0.1, 5.7) 1.15 (0.4, 6.0)
Received N1 DMT prior to IFN 9 (60.0) 5 (14.3) 34 (29.3) 17 (12.9)
Hospitalized for initial relapse 13 (86.7) 27 (77.1) 54 (46.6) 77 (58.3)
Treated with steroids for initial relapse 13 (86.7) 28 (80.0) 60 (51.7) 76 (57.6)
Data presented as n (%) unless speciﬁed otherwise.
DMT, disease-modifying therapy; IFN, interferon; ROW, rest of the world; SD, standard deviation.
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terns in the US and the ROW. Patients in the US had a higher frequency
of other DMT use prior to initiation of sc IFN β-1a, and stayed on sc IFN
β-1a treatment for a shorter time. The explanation for the higher fre-
quency of other DMT use prior to initiation sc IFN 1a in theUS compared
to other countries is unknown. One possibility is that since low-dose
low-frequency IFN β-1a had the greatest market share during this peri-
od in the US and it could have been preferentially given to younger pa-
tients. Furthermore, sc IFN β-1a was ﬁrst available in Europe in 1998,
but was not available in the US until 2002 so may have not been used
as often. Further research is needed to determine whether these differ-
ences can be explained by other differences in prescribing habits and ac-
cess to healthcare resources among countries.
On-treatment relapses occurred more frequently among patients
from the US. It is unclear whether this represents varying disease pat-
terns due to different racial and ethnic composition or differences in ac-
cess to healthcare resources, leading to increased reporting of relapses.
Different availability of other treatments is likely to have contributed
to the increased switching rate among patients from the US; however,
the relative inﬂuence of disease factors versus healthcare practice fac-
tors cannot be determined from these data.
While sc IFN β-1a was well tolerated overall, there was a higher in-
cidence of injection-site reactions amongpatients from theUS. One pos-
sible explanation is that different formulations of sc IFN β-1a were used
across the countries in this analysis. From 2007, a new serum-free for-
mulation was gradually introduced in Europe and other regions, de-
signed to reduce immunogenicity and improve local tolerability of the
treatment. This formulation has been associated with an incidence of
injection-site reactions approximately threefold lower than that found
in historical studies involving the original formulation [12]. The new for-
mulation has not been approved in the US, and therefore US patients in
the present study were treated with the original, serum-containing for-
mulation. The transition between formulations may also haveTable 3
Dose and duration of sc IFN β-1a treatment and treatment status at the end of the observation
Variable Preadolescents (
US (n = 15)
First treatment dose
44 μg tiw 8 (53.3)
22 μg tiw 4 (26.7)
Other dosagea 3 (20.0)
Time on treatment (years)
Mean (SD) 0.67 (0.76)
Median (range) 0.42 (0.0, 2.3)
Status of sc IFN β-1a treatment at end of observation period
Ongoing treatment 8 (53.3)
Switched to other DMT 5 (33.3)
Discontinued all treatment 2 (13.3)
Data presented as n (%) unless speciﬁed otherwise.
DMD, disease-modifying therapy; IFN, interferon; ROW, rest of the world; sc, subcutaneous; SD
a Data from some patients are not included because these patients had received an initial docontributed to the higher incidence of ‘ﬂu-like’ symptoms in the ROW
population because, similarly towhen initiating IFN, a transient increase
in ‘ﬂu-like’ symptoms is possible when patients switch to another for-
mulation [11,12].
The main limitation of this study is its retrospective nature. Some of
the variables examined in this post hoc analysis, such as BMI, were out-
side the primary focus of the original investigation, and therefore there
were high rates ofmissing data. EDSS score at the time of attackwas un-
fortunately notmeasured sowe are unable to speculate on the impact of
relapse severity. Moreover, as this was not a clinical trial, there were no
preset algorithms for the evaluation of relapses, treatment decisions,
and subsequent management. However, the observed differences in
practice patterns and some clinical features can generate further hy-
pothesis testing in prospective studies. To minimize the potential selec-
tion bias inherent to the retrospective patient ascertainment, the study
sought to assess all pediatric patients who commenced treatment with
sc IFN β-1a prior to 30 June 2009 in the participating centers. However,
patients from different centers had varying exposure to sc IFN β-1a and
varying follow-up times, and confounding factors included exposure to
other medications, co-morbidities, gender, and age at the time of sc IFN
β-1a initiation. In addition, biases could also have been introduced by
the site, country, or region due to differences in treatment practices.
Taken together, the ﬁndings presented here show that, compared
with the ROW, adolescents with MS from the US have a higher BMI
and appear to be managed differently relative to their ROW counter-
parts: a greater variety of DMTs are prescribed, treatment is started
more quickly from the time of diagnosis, and there is a greater tendency
to switch therapies. Future studies should conﬁrm whether patients
from the US have higher BMI and how this may relate to other clinical
features. Prospective studies could identify any regional differences in
disease course and ascertain how demographic features may be associ-
atedwith clinical outcomes. Healthcare practicesworldwide should also
be compared and examined for their effects on outcomes.period by region.
b12 years) Adolescents (12–17 years)
ROW (n = 35) US (n = 116) ROW (n = 132)
1 (2.9) 98 (86.7) 32 (25.0)
28 (80.0) 10 (8.8) 74 (57.8)
6 (17.1) 5 (4.4) 22 (17.2)
3.95 (3.44) 1.46 (1.04) 2.45 (2.13)
3.28 (0.1, 12.5) 1.16 (0.0, 4.4) 1.52 (0.0, 7.8)
29 (82.9) 69 (59.5) 97 (73.5)
1 (2.9) 33 (28.4) 21 (15.9)
5 (14.3) 14 (12.1) 14 (10.6)
, standard deviation; tiw, three times weekly.
se other than 44 or 22 μg tiw.
Table 4
Incidence of prespeciﬁed medical events by region.
Region Preadolescents (b12 years) Adolescents (12–17 years)
US (n = 15) ROW (n = 35) US (n = 116) ROW (n = 132)
Patients with at least one prespeciﬁed event 5 (33.3) 24 (68.6) 65 (56.0) 70 (53.0)
Injection-site reactions 3 (20.0) 6 (17.1) 44 (37.9) 29 (22.0)
‘Flu-like’ symptoms 0 14 (40.0) 24 (20.7) 36 (27.3)
Hepatic disorders 3 (20.0) 5 (14.3) 12 (10.3) 24 (18.2)
Blood cell abnormalities (e.g. thrombocytopenia, leukopenia, anemia) 1 (6.7) 1 (2.9) 2 (1.7) 10 (7.6)
Allergic reactions (e.g. rash, urticaria and anaphylaxis) 0 1 (2.9) 3 (2.6) 0
Epilepsy and convulsive disorders 0 1 (2.9) 2 (1.7) 1 (0.8)
Thyroid dysfunction 0 1 (2.9) 0 2 (1.5)
Autoimmune diseases 0 0 2 (1.7) 0
Bone/epiphyseal and cartilage disorders 0 1 (2.9) 0 1 (0.8)
Serious infections 0 0 2 (1.7) 0
Malignancies 0 1 (2.9) 0 0
ROW, rest of the world.
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